Replimune (REPL) EBT (2017 - 2025)

Replimune has disclosed EBT across 9 years of filings, most recently posting -$71.2 million for Q4 2025.

• EBT for Q4 2025 came in at -$71.2 million, down 8.33% year-over-year; the trailing twelve-month figure through Dec 2025 was -$314.7 million (down 38.21% YoY), and the FY2025 annual result was -$246.8 million, down 14.6% from the prior year.
• EBT came in at -$71.2 million for Q4 2025 at Replimune, up from -$82.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$22.1 million in Q1 2021 to a low of -$87.2 million in Q2 2025.
• The 5-year median for EBT is -$50.0 million (2023), against an average of -$50.8 million.
• Across the five-year window, EBT gained 11.93% in 2024 and plunged 62.13% in 2025, its largest moves.
• Replimune's EBT stood at -$29.6 million in 2021, then tumbled by 34.04% to -$39.7 million in 2022, then fell by 27.61% to -$50.6 million in 2023, then declined by 29.85% to -$65.8 million in 2024, then declined by 8.33% to -$71.2 million in 2025.
• The last three EBT figures came in at -$71.2 million (Q4 2025), -$82.1 million (Q3 2025), and -$87.2 million (Q2 2025), per Business Quant data.